Issue link: https://www.e-digitaleditions.com/i/1518209
34 April 2024 Inhalation Nasal formulation development and manufacturing Renaissance Lakewood offers contract development and manufacturing for nasal sprays. We can support all stages of projects, from formulation development through commercial manufacturing. With over 20 years of experience, our team can support a wide range of development activities including formulation development/optimization, spray method develop- ment, device selection, clinical trial material, process development and stability studies. In addition, we can support a wide range of nasal spray devices, includ- ing unit-dose, bi-dose and multi-dose (preserved and non-preserved formulations). Renaissance Lakewood US: +1 732 367-9000 www.renpharm.com DPI formulation development and manufacturing For 25 years, Lonza has provided integrated dry pow- der inhaler (DPI) development services to advance small molecules. Our premier particle engineering platform consists of integrated product development, including optimized particle engineering, precision micro-dosing, rapid screening, clinically relevant test- ing and GMP production. Our global facilities are equipped with world-class equipment and expertise to provide end-to-end services for respiratory drugs. Contact us for more information. Lonza Small Molecules US: +1 813 286-0404 www.lonza.com Development and manufacturing of greener pMDIs As a global combination product CDMO and the inventor of the first metered dose inhaler, Kindeva Drug Delivery develops and manufactures a full spectrum of pulmonary and nasal, injectable and transdermal products. We deliver industry- leading, phase-appropriate analytical methods, hardware design, and formulation across pressurized metered dose inhalers (pMDIs) and other platforms, with extensive expertise in generics. Our commitment to innovation extends to sustainability. We will be one of the first CDMOs to offer a commercial green propel- lant line, set to launch in 2025, offering propellants that provide 90-99.9% lower Global Warming Poten- tial (GWP) than current options. We work with you to bring life-changing therapies to patients worldwide. Kindeva Drug Delivery US: +1 800 643-8086 www.kindevadd.com Formulation, device and development services Vectura has 25 years of experience in helping cus- tomers to integrate formulation, device and develop- ment services to accelerate their inhalation products through the phases of drug development. With expertise in a range of technology platforms, includ- ing dry powder inhalers (DPIs), pressurized metered dose inhalers (pMDIs) and smart nebulizers, Vectura offers flexibility and a fully-integrated approach, from preclinical formulation optimization and device selection, through scale-up, and GMP product and device manufacturing. Vectura UK: +44 1249 667700 info@vectura.com www.vectura.com